Grufity logo
Grufity logo
TNXP

TNXP - Tonix Pharmaceuticals Holding Corp Stock Price, Fair Value and News

$11.63+0.10 (+0.87%)
Market Closed as of 16 Jun 2026, 04:00 pm ET

57/100

TNXP

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

57/100

TNXP

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

TNXP Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

TNXP Price Action

Last 7 days

-1.5%

Last 30 days

-26.7%

Last 90 days

-22.9%

Trailing 12 Months

-63.9%

TNXP RSI Chart

TNXP Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

TNXP Valuation

Market Cap

163.8M

Price/Earnings (Trailing)

-1.11

Price/Sales (Trailing)

9.33

EV/EBITDA

0.09

Price/Free Cashflow

-1.25

TNXP Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

TNXP Fundamentals

TNXP Revenue

Revenue (TTM)

17.6M

Rev. Growth (Yr)

183.16%

Rev. Growth (Qtr)

27.61%

TNXP Earnings

Earnings (TTM)

-147.4M

Earnings Growth (Yr)

-138.84%

Earnings Growth (Qtr)

14.32%

TNXP Profitability

Operating Margin

58.56%

EBT Margin

-120.32%

Return on Equity

-64.89%

Return on Assets

-57.15%

Free Cashflow Yield

-79.76%

TNXP Investor Care

Shares Dilution (1Y)

106.54%

Diluted EPS (TTM)

-14.59

TNXP Alerts

  • 2 major insider buys recently.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
202617.6M---
202510.0M9.8M10.3M13.1M
20248.3M8.9M9.5M10.1M
2023---7.8M
Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About Tonix Pharmaceuticals Holding Corp

TNXP
Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, develops therapeutics and vaccines to treat and prevent human disease and alleviate suffering. Its portfolio includes immunology, rare disease, infectious disease, and central nervous system (CNS) product candidates. The company's immunology portfolio includes biologics to address organ transplant rejection, autoimmunity, and cancer, including TNX-1500, a humanized monoclonal antibody targeting CD40-ligand being developed to treat autoimmune conditions. Its rare disease portfolio comprises TNX-2900 for the treatment of Prader-Willi syndrome. The company's infectious disease pipeline includes TNX-801, a vaccine to prevent smallpox and monkeypox; TNX-1840 and TNX-1850 that are live virus vaccines based on its recombinant pox vaccine (RPV) platform for COVID-19; and TNX-102 SL, a CNS product candidate to treat Long COVID, a chronic post-acute COVID-19 condition. Its CNS portfolio includes small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions, including TNX-102 SL, which is in mid-Phase 3 development for the management of fibromyalgia; TNX-1900 that is in development for the prevention of migraine headache; and TNX-1300, a recombinant protein enzyme to treat cocaine intoxication. The company was founded in 2007 and is headquartered in Chatham, New Jersey.
 CEO
 WEBSITEtonixpharma.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES117

Tonix Pharmaceuticals Holding Corp Frequently Asked Questions

TNXP is the stock ticker symbol of Tonix Pharmaceuticals Holding Corp. Every public company that trades on a stock exchange gets a ticker symbol.

As of Mon Jun 15 2026, market cap of Tonix Pharmaceuticals Holding Corp is 163.79 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Mon Jun 15 2026, TNXP's PE ratio (Price to Earnings) is -1.11 and Price to Sales (PS) ratio is 9.33. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TNXP PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Tonix Pharmaceuticals Holding Corp has provided -0.798 (multiply by 100 for percentage) rate of return.